(Q53538901)

15 May 2018

title

Autologous non-myeloablative hematopoietic stem cell transplantation in patients with systemic sclerosis. (English)

1 reference

15 May 2018

author name string

Oyama Y

1

1 reference

15 May 2018

Barr WG

2

1 reference

15 May 2018

Statkute L

3

1 reference

15 May 2018

Corbridge T

4

1 reference

15 May 2018

Gonda EA

5

1 reference

15 May 2018

Jovanovic B

6

1 reference

15 May 2018

Testori A

7

1 reference

15 May 2018

Burt RK

8

1 reference

15 May 2018

language of work or name

English

0 references

publication date

23 July 2007

1 reference

15 May 2018

Bone Marrow Transplantation

published in

1 reference

15 May 2018

volume

40

1 reference

15 May 2018

issue

6

1 reference

15 May 2018

page(s)

549-555

1 reference

15 May 2018

https://scigraph.springernature.com/pub.10.1038/sj.bmt.1705782

exact match

0 references

cites work

D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

Microchimerism: an investigative frontier in autoimmunity and transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Defective vasculogenesis in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Scleroderma: from cell and molecular mechanisms to disease models

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Phase I/II trial of autologous stem cell transplantation in systemic sclerosis: procedure related mortality and impact on skin disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Autologous bone marrow transplantation in the treatment of refractory systemic sclerosis: early results from a French multicentre phase I-II study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative to lymphoablative transplant regimens

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Mobilization, harvesting and selection of peripheral blood stem cells in patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

The rationale behind autologous autoimmune hematopoietic stem cell transplant conditioning regimens: concerns over the use of total-body irradiation in systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Cyclophosphamide versus placebo in scleroderma lung disease.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Engraftment syndrome: a common cause for rash and fever following autologous hematopoietic stem cell transplantation for multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Gastric involvement in systemic sclerosis: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Immunosuppression with chlorambucil, versus placebo, for scleroderma. Results of a three-year, parallel, randomized, double-blind study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

5-fluorouracil in the treatment of scleroderma: a randomised, double blind, placebo controlled international collaborative study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Pilot study of anti-thymocyte globulin plus mycophenolate mofetil in recent-onset diffuse scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Interferon-alpha does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Treatment of systemic sclerosis with recombinant interferon-gamma. A phase I/II clinical trial

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Treatment of patients with systemic sclerosis with extracorporeal photochemotherapy (photopheresis)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Improved pulmonary function in systemic sclerosis after treatment with cyclophosphamide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Intravenous cyclophosphamide pulse therapy for the treatment of lung disease associated with scleroderma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Cyclophosphamide is associated with pulmonary function and survival benefit in patients with scleroderma and alveolitis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.BMT.1705782

7 January 2021

Identifiers

DOI

10.1038/SJ.BMT.1705782

1 reference

15 May 2018

PubMed ID

17646844

1 reference

15 May 2018